全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

Role of Orphan Nuclear Receptor DAX-1/NR0B1 in Development, Physiology, and Disease

DOI: 10.1155/2014/582749

Full-Text   Cite this paper   Add to My Lib

Abstract:

DAX-1/NR0B1 is an unusual orphan receptor that has a pivotal role in the development and function of steroidogenic tissues and of the reproductive axis. Recent studies have also indicated that this transcription factor has an important function in stem cell biology and in several types of cancer. Here I critically review the most important findings on the role of DAX-1 in development, physiology, and disease of endocrine tissues since the cloning of its gene twenty years ago. 1. Introduction Nuclear hormone receptors are intracellular proteins that are responsible for sensing lipophilic substances and mediating their physiological actions, directly regulating the expression of target genes through binding to DNA. Nuclear receptors are implicated in a large variety of biological processes and have a special importance in development and endocrine functions (reviewed in [1]). A common feature of the members of this protein family is the presence of a conserved domain in the carboxyterminal part of the protein, which has the capacity to bind ligands (ligand-binding domain: LBD) modulating the transcriptional activity of the receptor and which folds as an antiparallel alpha-helical sandwich [2]. However, ligands are not known for all family members: the terminology of “orphan” is then used to indicate those proteins, which often possess a defined transcriptional function in the apparent absence of ligands. This spotlight paper is focused on a peculiar orphan receptor, DAX-1 (NR0B1 in the nuclear receptor official nomenclature), and will review the most important findings about its role in development, physiology, and disease. 2. Cloning and Structure of DAX-1: An Unusual Orphan Receptor Cloning of the DAX-1 gene dates back to 1994. Previous studies by Bardoni and colleagues described a specific disorder of sex development, causing male-to-female phenotypic sex reversal (dosage-sensitive sex (DSS) reversal) in individuals bearing a normal SRY gene, associated with duplication of a minimal region spanning approximately 160?kb in chromosome Xp21 [3]. Cloning of expressed sequences in this region led to the identification of a two-exon gene encoding a novel member of the nuclear receptor family [4]. Remarkably, deletions, frameshift, missense, and stop mutations in this gene were found in patients affected with adrenal hypoplasia congenita (AHC), a congenital disorder characterized by impaired development of the adrenal cortex that can lead to adrenal insufficiency and is associated with hypogonadotropic hypogonadism (HHG) after puberty [4, 5]. Given its

References

[1]  D. J. Mangelsdorf, C. Thummel, M. Beato et al., “The nuclear receptor super-family: the second decade,” Cell, vol. 83, no. 6, pp. 835–839, 1995.
[2]  J. M. Wurtz, W. Bourguet, J. P. Renaud, et al., “A canonical structure for the ligand-binding domain of nuclear receptors,” Nature Structural Biology, vol. 3, no. 1, pp. 87–94, 1996.
[3]  B. Bardoni, E. Zanaria, S. Guioli et al., “A dosage sensitive locus at chromosome Xp21 is involved in male to female sex reversal,” Nature Genetics, vol. 7, no. 4, pp. 497–501, 1994.
[4]  E. Zanaria, F. Muscatelli, B. Bardoni et al., “An unusual member of the nuclear hormone receptor superfamily responsible for X-linked adrenal hypoplasia congenita,” Nature, vol. 372, no. 6507, pp. 635–641, 1994.
[5]  F. Muscatelli, T. M. Strom, A. P. Walker et al., “Mutations in the DAX-1 gene give rise to both X-linked adrenal hypoplasia congentia and hypogonadotropic hypogonadism,” Nature, vol. 372, no. 6507, pp. 672–676, 1994.
[6]  A. Swain, E. Zanaria, A. Hacker, R. Lovell-Badge, and G. Camerino, “Mouse Dax1 expression is consistent with a role in sex determination as well as in adrenal and hypothalamus function,” Nature Genetics, vol. 12, no. 4, pp. 404–409, 1996.
[7]  P. Parma, E. Pailhoux, C. Puissant, and C. Cotinot, “Porcine Dax-1 gene: isolation and expression during gonadal development,” Molecular and Cellular Endocrinology, vol. 135, no. 1, pp. 49–58, 1997.
[8]  C. A. Smith, V. Clifford, P. S. Western, S. A. Wilcox, K. S. Bell, and A. H. Sinclair, “Cloning and expression of a DAX1 homologue in the chicken embryo,” Journal of Molecular Endocrinology, vol. 24, no. 1, pp. 23–32, 2000.
[9]  P. S. Western, J. L. Harry, J. A. Marshall Graves, and A. H. Sinclair, “Temperature-dependent sex determination in the American alligator: expression of SF1, WT1 and DAX1 during gonadogenesis,” Gene, vol. 241, no. 2, pp. 223–232, 2000.
[10]  J. Sugita, M. Takase, and M. Nakamura, “Expression of Dax-1 during gonadal development of the frog,” Gene, vol. 280, no. 1-2, pp. 67–74, 2001.
[11]  D.-S. Wang, T. Kobayashi, B. Senthilkumaran et al., “Molecular cloning of DAX1 and SHP cDNAs and their expression patterns in the Nile tilapia, Oreochromis niloticus,” Biochemical and Biophysical Research Communications, vol. 297, no. 3, pp. 632–640, 2002.
[12]  L. C. Torres Maldonado, A. Landa Piedra, N. Moreno Mendoza, A. Marmolejo Valencia, A. Meza Martínez, and H. Merchant Larios, “Expression profiles of Dax1, Dmrt1, and Sox9 during temperature sex determination in gonads of the sea turtle Lepidochelys olivacea,” General and Comparative Endocrinology, vol. 129, no. 1, pp. 20–26, 2002.
[13]  W. Seol, H. S. Choi, and D. D. Moore, “An orphan nuclear hormone receptor that lacks a DNA binding domain and heterodimerizes with other receptors,” Science, vol. 272, pp. 1336–1339, 1996.
[14]  A. Ehrlund and E. Treuter, “Ligand-independent actions of the orphan receptors/corepressors DAX-1 and SHP in metabolism, reproduction and disease,” The Journal of Steroid Biochemistry and Molecular Biology, vol. 130, pp. 169–179, 2012.
[15]  Y. Ikeda, A. Swain, T. Weber, et al., “Steroidogenic factor 1 and Dax-1 colocalize in multiple cell lineages: potential links in endocrine development,” Molecular Endocrinology, vol. 10, pp. 1261–1272, 1996.
[16]  M. W. Nachtigal, Y. Hirokawa, D. L. Enyeart-VanHouten, J. N. Flanagan, G. D. Hammer, and H. A. Ingraham, “Wilms' tumor 1 and Dax-1 modulate the orphan nuclear receptor SF-1 in sex-specific gene expression,” Cell, vol. 93, no. 3, pp. 445–454, 1998.
[17]  Y. Ikeda, Y. Takeda, T. Shikayama, T. Mukai, S. Hisano, and K.-I. Morohashi, “Comparative localization of Dax-1 and Ad4BP/SF-1 during development of the hypothalamic-pituitary-gonadal axis suggests their closely related and distinct functions,” Developmental Dynamics, vol. 220, no. 4, pp. 363–376, 2001.
[18]  T. Mukai, M. Kusaka, K. Kawabe et al., “Sexually dimorphic expression of Dax-1 in the adrenal cortex,” Genes to Cells, vol. 7, no. 7, pp. 717–729, 2002.
[19]  K. T. Tamai, L. Monaco, T. P. Alastalo, E. Lalli, M. Parvinen, and P. Sassone-Corsi, “Hormonal and developmental regulation of DAX-1 expression in Sertoli cells,” Molecular Endocrinology, vol. 10, no. 12, pp. 1561–1569, 1996.
[20]  S. Mesiano and R. B. Jaffe, “Developmental and functional biology of the primate fetal adrenal cortex,” Endocrine Reviews, vol. 18, pp. 378–403, 1997.
[21]  N. A. Hanley, W. E. Rainey, D. I. Wilson, S. G. Ball, and K. L. Parker, “Expression profiles of SF-1, DAX1, and CYP17 in the human fetal adrenal gland: potential interactions in gene regulation,” Molecular Endocrinology, vol. 15, no. 1, pp. 57–68, 2001.
[22]  N. A. Hanley, D. M. Hagan, M. Clement-Jones et al., “SRY, SOX9, and DAX1 expression patterns during human sex determination and gonadal development,” Mechanisms of Development, vol. 91, no. 1-2, pp. 403–407, 2000.
[23]  X. Luo, Y. Ikeda, and K. L. Parker, “A cell-specific nuclear receptor is essential for adrenal and gonadal development and sexual differentiation,” Cell, vol. 77, no. 4, pp. 481–490, 1994.
[24]  K. L. Parker and B. P. Schimmer, “Steroidogenic factor 1: a key determinant of endocrine development and function,” Endocrine Reviews, vol. 18, pp. 361–377, 1997.
[25]  Y. Ikeda, W.-H. Shen, H. A. Ingraham, and K. L. Parker, “Developmental expression of mouse steroidogenic factor-1, an essential regulator of the steroid hydroxylases,” Molecular Endocrinology, vol. 8, no. 5, pp. 654–662, 1994.
[26]  I. N. Krylova, E. P. Sablin, J. Moore et al., “Structural analyses reveal phosphatidyl inositols as ligands for the NR5 orphan receptors SF-1 and LRH-1,” Cell, vol. 120, no. 3, pp. 343–355, 2005.
[27]  Y. Li, M. Choi, G. Cavey et al., “Crystallographic identification and functional characterization of phospholipids as ligands for the orphan nuclear receptor steroidogenic factor-1,” Molecular Cell, vol. 17, no. 4, pp. 491–502, 2005.
[28]  W. Wang, C. Zhang, A. Marimuthu et al., “The crystal structures of human steroidogenic factor-1 and liver receptor homologue-1,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 21, pp. 7505–7510, 2005.
[29]  M. Ito, R. Yu, and J. L. Jameson, “DAX-1 inhibits SF-1-mediated transactivation via a carboxy-terminal domain that is deleted in adrenal hypoplasia congenita,” Molecular and Cellular Biology, vol. 17, pp. 1476–1483, 1997.
[30]  E. Lalli, B. Bardoni, E. Zazopoulos, et al., “A transcriptional silencing domain in DAX-1 whose mutation causes adrenal hypoplasia congenita,” Molecular Endocrinology, vol. 11, no. 13, pp. 1950–1960, 1997.
[31]  E. Zazopoulos, E. Lalli, D. M. Stocco, and P. Sassone-Corsi, “DNA binding and transcriptional repression by DAX-1 blocks steroidogenesis,” Nature, vol. 390, no. 6657, pp. 311–315, 1997.
[32]  E. Lalli, M. H. Melner, D. M. Stocco, and P. Sassone-Corsi, “DAX-1 blocks steroid production at multiple levels,” Endocrinology, vol. 139, no. 10, pp. 4237–4243, 1998.
[33]  B. Ragazzon, A.-M. Lefran?ois-Martinez, P. Val et al., “Adrenocorticotropin-dependent changes in SF-1/DAX-1 ratio influence steroidogenic genes expression in a novel model of glucocorticoid-producing adrenocortical cell lines derived from targeted tumorigenesis,” Endocrinology, vol. 147, no. 4, pp. 1805–1818, 2006.
[34]  P. S. Babu, D. L. Bavers, F. Beuschlein et al., “Interaction between Dax-1 and steroidogenic factor-1 in vivo: increased adrenal responsiveness to ACTH in the absence of Dax-1,” Endocrinology, vol. 143, no. 2, pp. 665–673, 2002.
[35]  E. Lalli and P. Sassone-Corsi, “DAX-1, an unusual orphan receptor at the crossroads of steroidogenic function and sexual differentiation,” Molecular Endocrinology, vol. 17, no. 8, pp. 1445–1453, 2003.
[36]  A. Ehrlund, E. Holter Anthonisen, N. Gustafsson et al., “E3 ubiquitin ligase RNF31 cooperates with DAX-1 in transcriptional repression of steroidogenesis,” Molecular and Cellular Biology, vol. 29, no. 8, pp. 2230–2242, 2009.
[37]  T. P. Burris, W. Guo, T. Le, and E. R. B. McCabe, “Identification of a putative steroidogenic factor-1 response element in the DAX-1 promoter,” Biochemical and Biophysical Research Communications, vol. 214, no. 2, pp. 576–581, 1995.
[38]  E. Vilain, W. Guo, Y. H. Zhang, and E. R. McCabe, “DAX1 gene expression upregulated by steroidogenic factor 1 in an adrenocortical carcinoma cell line,” Biochemical and Molecular Medicine, vol. 61, no. 1, pp. 1–8, 1997.
[39]  K. Kawabe, T. Shikayama, H. Tsuboi et al., “Dax-1 as one of the target genes of Ad4BP/SF-1,” Molecular Endocrinology, vol. 13, no. 8, pp. 1267–1284, 1999.
[40]  C. Hoyle, V. Narvaez, G. Alldus, R. Lovell-Badge, and A. Swain, “Dax1 expression is dependent on steroidogenic factor 1 in the developing gonad,” Molecular Endocrinology, vol. 16, no. 4, pp. 747–756, 2002.
[41]  M. Doghman, T. Karpova, G. A. Rodrigues et al., “Increased steroidogenic factor-1 dosage triggers adrenocortical cell proliferation and cancer,” Molecular Endocrinology, vol. 21, no. 12, pp. 2968–2987, 2007.
[42]  M. Doghman, B. C. Figueiredo, M. Volante, M. Papotti, and E. Lalli, “Integrative analysis of SF-1 transcription factor dosage impact on genome-wide binding and gene expression regulation,” Nucleic Acids Research, vol. 41, no. 19, pp. 8896–8907, 2013.
[43]  E. Lalli, M. Doghman, P. Latre de Late, A. El Wakil, and I. Mus-Veteau, “Beyond steroidogenesis: novel target genes for SF-1 discovered by genomics,” Molecular and Cellular Endocrinology, vol. 371, no. 1-2, pp. 154–159, 2013.
[44]  M. Zubair, K. L. Parker, and K.-I. Morohashi, “Developmental links between the fetal and adult zones of the adrenal cortex revealed by lineage tracing,” Molecular and Cellular Biology, vol. 28, no. 23, pp. 7030–7040, 2008.
[45]  T. Suzuki, M. Kasahara, H. Yoshioka, K.-I. Morohashi, and K. Umesono, “LXXLL-related motifs in Dax-1 have target specificity for the orphan nuclear receptors Ad4BP/SF-1 and LRH-1,” Molecular and Cellular Biology, vol. 23, no. 1, pp. 238–249, 2003.
[46]  H. Zhang, J. S. Thomsen, L. Johansson, J.-?. Gustafsson, and E. Treuter, “DAX-1 functions as an LXXLL-containing corepressor for activated estrogen receptors,” The Journal of Biological Chemistry, vol. 275, no. 51, pp. 39855–39859, 2000.
[47]  E. Holter, N. Kotaja, S. M?kela et al., “Inhibition of androgen receptor (AR) function by the reproductive orphan nuclear receptor DAX-1,” Molecular Endocrinology, vol. 16, no. 3, pp. 515–528, 2002.
[48]  I. U. Agoulnik, W. C. Krause, W. E. Bingman III et al., “Repressors of androgen and progesterone receptor action,” The Journal of Biological Chemistry, vol. 278, no. 33, pp. 31136–31148, 2003.
[49]  K.-H. Song, Y.-Y. Park, K. C. Park et al., “The atypical orphan nuclear receptor DAX-1 interacts with orphan nuclear receptor Nur77 and represses its transactivation,” Molecular Endocrinology, vol. 18, no. 8, pp. 1929–1940, 2004.
[50]  Y.-Y. Park, S.-W. Ahn, H.-J. Kim et al., “An autoregulatory loop controlling orphan nuclear receptor DAX-1 gene expression by orphan nuclear receptor ERRγ,” Nucleic Acids Research, vol. 33, no. 21, pp. 6756–6768, 2005.
[51]  J. Zhou, R. H. Oakley, and J. A. Cidlowski, “DAX-1 (dosage-sensitive sex reversal-adrenal hypoplasia congenita critical region on the X-chromosome, gene 1) selectively inhibits transactivation but not transrepression mediated by the glucocorticoid receptor in a LXXLL-dependent manner,” Molecular Endocrinology, vol. 22, no. 7, pp. 1521–1534, 2008.
[52]  G. S. Kim, G. Y. Lee, B. Nedumaran et al., “The orphan nuclear receptor DAX-1 acts as a novel transcriptional corepressor of PPARγ,” Biochemical and Biophysical Research Communications, vol. 370, no. 2, pp. 264–268, 2008.
[53]  B. Nedumaran, S. Hong, Y.-B. Xie et al., “DAX-1 acts as a novel corepressor of orphan nuclear receptor HNF4α and negatively regulates gluconeogenic enzyme gene expression,” The Journal of Biological Chemistry, vol. 284, no. 40, pp. 27511–27523, 2009.
[54]  B. Nedumaran, G. S. Kim, S. Hong et al., “Orphan nuclear receptor DAX-1 acts as a novel corepressor of liver X receptor α and inhibits hepatic lipogenesis,” The Journal of Biological Chemistry, vol. 285, no. 12, pp. 9221–9232, 2010.
[55]  J. Li, Y. Lu, R. Liu et al., “DAX1 suppresses FXR transactivity as a novel co-repressor,” Biochemical and Biophysical Research Communications, vol. 412, no. 4, pp. 660–666, 2011.
[56]  E. M. Laurenzana, T. Chen, M. Kannuswamy et al., “The orphan nuclear receptor DAX-1 functions as a potent corepressor of the constitutive androstane receptor (NR1I3),” Molecular Pharmacology, vol. 82, no. 5, pp. 918–928, 2012.
[57]  K. Uranishi, T. Akagi, C. Sun, H. Koide, and T. Yokota, “Dax1 associates with Esrrb and regulates its function in embryonic stem cells,” Molecular and Cellular Biology, vol. 33, no. 10, pp. 2056–2066, 2013.
[58]  C. Sun, Y. Nakatake, T. Akagi et al., “Dax1 binds to Oct3/4 and inhibits its transcriptional activity in embryonic stem cells,” Molecular and Cellular Biology, vol. 29, no. 16, pp. 4574–4583, 2009.
[59]  M. Kinsey, R. Smith, A. K. Iyer, E. R. B. McCabe, and S. L. Lessnick, “EWS/FLI and its downstream target NR0B1 interact directly to modulate transcription and oncogenesis in Ewing's sarcoma,” Cancer Research, vol. 69, no. 23, pp. 9047–9055, 2009.
[60]  P. R. Manna, M. T. Dyson, Y. Jo, and D. M. Stocco, “Role of dosage-sensitive sex reversal, adrenal hypoplasia congenita, critical region on the x chromosome, gene 1 in protein kinase a- and protein kinase c-mediated regulation of the steroidogenic acute regulatory protein expression in mouse leydig tumor cells: mechanism of action,” Endocrinology, vol. 150, no. 1, pp. 187–199, 2009.
[61]  E. P. Sablin, A. Woods, I. N. Krylova, P. Hwang, H. A. Ingraham, and R. J. Fletterick, “The structure of corepressor Dax-1 bound to its target nuclear receptor LRH-1,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 47, pp. 18390–18395, 2008.
[62]  A. K. Iyer, Y.-H. Zhang, and E. R. B. McCabe, “Dosage-sensitive sex reversal adrenal hypoplasia congenita critical region on the X chromosome, gene 1 (DAX1) (NR0B1) and Small Heterodimer Partner (SHP) (NR0B2) form homodimers individually, as well as DAX1-SHP heterodimers,” Molecular Endocrinology, vol. 20, no. 10, pp. 2326–2342, 2006.
[63]  P. A. Crawford, C. Dorn, Y. Sadovsky, and J. Milbrandt, “Nuclear receptor DAX-1 recruits nuclear receptor corepressor N-CoR to steroidogenic factor 1,” Molecular and Cellular Biology, vol. 18, no. 5, pp. 2949–2956, 1998.
[64]  B. Altincicek, S. P. Tenbaum, U. Drossel, D. Thormeyer, R. Renkawitz, and A. Baniahmad, “Interaction of the corepressor alien with DAX-1 is abrogated by mutations of DAX-1 involved in adrenal hypoplasia congenita,” The Journal of Biological Chemistry, vol. 275, no. 11, pp. 7662–7667, 2000.
[65]  S. G. Lehmann, E. Lalli, and P. Sassone-Corsi, “X-linked adrenal hypoplasia congenita is caused by abnormal nuclear localization of the DAX-1 protein,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 12, pp. 8225–8230, 2002.
[66]  S. G. Lehmann, J.-M. Wurtz, J.-P. Renaud, P. Sassone-Corsi, and E. Lalli, “Structure-function analysis reveals the molecular determinants of the impaired biological function of DAX-1 mutants in AHC patients,” Human Molecular Genetics, vol. 12, no. 9, pp. 1063–1072, 2003.
[67]  S. Gray and M. Levine, “Transcriptional repression in development,” Current Opinion in Cell Biology, vol. 8, pp. 358–364, 1996.
[68]  Y. Qiu, F. A. Pereira, F. J. DeMayo, J. P. Lydon, S. Y. Tsai, and M. J. Tsai, “Null mutation of mCOUP-TFI results in defects in morphogenesis of the glossopharyngeal ganglion, axonal projection, and arborization,” Genes & Development, vol. 11, no. 15, pp. 1925–1937, 1997.
[69]  F. A. Pereira, Q. Yuhong, G. Zhou, M.-J. Tsai, and S. Y. Tsai, “The orphan nuclear receptor COUP-TFII is required for angiogenesis and heart development,” Genes & Development, vol. 13, no. 8, pp. 1037–1049, 1999.
[70]  E. Lalli, K. Ohe, C. Hindelang, and P. Sassone-Corsi, “Orphan receptor DAX-1 is a shuttling RNA binding protein associated with polyribosomes via mRNA,” Molecular and Cellular Biology, vol. 20, no. 13, pp. 4910–4921, 2000.
[71]  B. Xu, W.-H. Yang, I. Gerin, C.-D. Hu, G. D. Hammer, and R. J. Koenig, “Dax-1 and steroid receptor RNA activator (SRA) function as transcriptional coactivators for steroidogenic factor 1 in steroidogenesis,” Molecular and Cellular Biology, vol. 29, no. 7, pp. 1719–1734, 2009.
[72]  O. Zwermann, F. Beuschlein, E. Lalli, A. Klink, P. Sassone-Corsi, and M. Reincke, “Clinical and molecular evidence for DAX-1 inhibition of steroidogenic factor-1-dependent ACTH receptor gene expression,” European Journal of Endocrinology, vol. 152, no. 5, pp. 769–776, 2005.
[73]  B. Ferraz-de-Souza, F. Martin, D. Mallet et al., “CBP/p300-interacting transactivator, with Glu/Asp-rich C-terminal domain, 2, and pre-B-cell leukemia transcription factor 1 in human adrenal development and disease,” Journal of Clinical Endocrinology and Metabolism, vol. 94, no. 2, pp. 678–683, 2009.
[74]  A. A. Verrijn Stuart, G. Ozisik, M. A. de Vroede et al., “Clinical case seminar: an amino-terminal DAX1 (NROB1) missense mutation associated with isolated mineralocorticoid deficiency,” Journal of Clinical Endocrinology and Metabolism, vol. 92, no. 3, pp. 755–761, 2007.
[75]  V. R. Kelly, B. Xu, R. Kuick, R. J. Koenig, and G. D. Hammer, “Dax1 up-regulates Oct4 expression in mouse embryonic stem cells via LRH-1 and SRA,” Molecular Endocrinology, vol. 24, no. 12, pp. 2281–2291, 2010.
[76]  J. Kim, D. Prawitt, N. Bardeesy et al., “The Wilms' tumor suppressor gene (wt1) product regulates Dax-1 gene expression during gonadal differentiation,” Molecular and Cellular Biology, vol. 19, no. 3, pp. 2289–2299, 1999.
[77]  B. Skinningsrud, E. S. Husebye, G. D. Gilfillan et al., “X-linked congenital adrenal hypoplasia with hypogonadotropic hypogonadism caused by an inversion disrupting a conserved noncoding element upstream of the NR0B1 (DAX1) gene,” Journal of Clinical Endocrinology and Metabolism, vol. 94, no. 10, pp. 4086–4093, 2009.
[78]  M. Barbaro, M. Oscarson, J. Schoumans, J. Staaf, S. A. Ivarsson, and A. Wedell, “Isolated 46,XY gonadal dysgenesis in two sisters caused by a Xp21.2 interstitial duplication containing the DAX1 gene,” Journal of Clinical Endocrinology and Metabolism, vol. 92, no. 8, pp. 3305–3313, 2007.
[79]  A. El Wakil and E. Lalli, “The Wnt/beta-catenin pathway in adrenocortical development and cancer,” Molecular and Cellular Endocrinology, vol. 332, no. 1-2, pp. 32–37, 2011.
[80]  S. Vainio, M. Heikkil?, A. Kispert, N. Chin, and A. P. McMahon, “Female development in mammals is regulated by Wnt-4 signalling,” Nature, vol. 397, no. 6718, pp. 405–409, 1999.
[81]  B. K. Jordan, M. Mohammed, S. T. Ching et al., “Up-regulation of WNT-4 signaling and dosage-sensitive sex reversal in humans,” American Journal of Human Genetics, vol. 68, no. 5, pp. 1102–1109, 2001.
[82]  H. Mizusaki, K. Kawabe, T. Mukai et al., “Dax-1 (dosage-sensitive sex reversal-adrenal hypoplasia congenita critical region on the X chromosome, gene 1) gene transcription is regulated by wnt4 in the female developing gonad,” Molecular Endocrinology, vol. 17, no. 4, pp. 507–519, 2003.
[83]  H. Osman, C. Murigande, A. Nadakal, and A. M. Capponi, “Repression of DAX-1 and induction of SF-1 expression: two mechanisms contributing to the activation of aldosterone biosynthesis in adrenal glomerulosa cells,” The Journal of Biological Chemistry, vol. 277, no. 43, pp. 41259–41267, 2002.
[84]  T. Yazawa, T. Mizutani, K. Yamada et al., “Involvement of cyclic adenosine 5′-monophosphate response element-binding protein, steroidogenic factor 1, and Dax-1 in the regulation of gonadotropin-inducible ovarian transcription factor 1 gene expression by follicle-stimulating hormone in ovarian granulosa cells,” Endocrinology, vol. 144, no. 5, pp. 1920–1930, 2003.
[85]  B. M. Gummow, J. O. Scheys, V. R. Cancelli, and G. D. Hammer, “Reciprocal regulation of a glucocorticoid receptor-steroidogenic factor-1 transcription complex on the Dax-1 promoter by glucocorticoids and adrenocorticotropic hormone in the adrenal cortex,” Molecular Endocrinology, vol. 20, no. 11, pp. 2711–2723, 2006.
[86]  G. B. Kletter, J. L. Gorski, and R. P. Kelch, “Congenital adrenal hypoplasia and isolated gonadotropin deficiency,” Trends in Endocrinology and Metabolism, vol. 2, no. 4, pp. 123–128, 1991.
[87]  R. L. Habiby, P. Boepple, L. Nachtigall, P. M. Sluss, W. F. Crowley Jr., and J. L. Jameson, “Adrenal hypoplasia congenita with hypogonadotropic hypogonadism. Evidence that DAX-1 mutations lead to combined hypothalamic and pituitary defects in gonadotropin production,” The Journal of Clinical Investigation, vol. 98, no. 4, pp. 1055–1062, 1996.
[88]  T. Takahashi, Y. Shoji, Y. Shoji, N. Haraguchi, I. Takahashi, and G. Takada, “Active hypothalamic-pituitary-gonadal axis in an infant with X-linked adrenal hypoplasia congenita,” The Journal of Pediatrics, vol. 130, no. 3, pp. 485–488, 1997.
[89]  K. B. Kaiserman, J. M. Nakamoto, M. E. Geffner, and E. R. B. McCabe, “Minipuberty of infancy and adolescent pubertal function in adrenal hypoplasia congenita,” Journal of Pediatrics, vol. 133, no. 2, pp. 300–302, 1998.
[90]  I. Takahashi, T. Takahashi, Y. Shoji, and G. Takada, “Prolonged activation of the hypothalamus-pituitary-gonadal axis in a child with X-linked adrenal hypoplasia congenita,” Clinical Endocrinology, vol. 53, no. 1, pp. 127–129, 2000.
[91]  D. P. Merke, T. Tajima, J. Baron, and G. B. Cutler Jr., “Hypogonadotropic hypogonadism in a female caused by an X-linked recessive mutation in the DAX1 gene,” The New England Journal of Medicine, vol. 340, no. 16, pp. 1248–1252, 1999.
[92]  J. C. Achermann, W.-X. Gu, T. J. Kotlar et al., “Mutational analysis of DAX1 in patients with hypogonadotropic hypogonadism or pubertal delay,” Journal of Clinical Endocrinology and Metabolism, vol. 84, no. 12, pp. 4497–4500, 1999.
[93]  G. Mantovani, G. Ozisik, J. C. Achermann et al., “Hypogonadotropic hypogonadism as a presenting feature of late-onset X-linked adrenal hypoplasia congenita,” Journal of Clinical Endocrinology and Metabolism, vol. 87, no. 1, pp. 44–48, 2002.
[94]  C. Frapsauce, C. Ravel, M. Legendre et al., “Birth after TESEICSI in a man with hypogonadotropic hypogonadism and congenital adrenal hypoplasia linked to a DAX-1 (NR0B1) mutation,” Human Reproduction, vol. 26, no. 3, pp. 724–728, 2011.
[95]  K.-Y. Loke, L. K.-S. Poh, W. W.-R. Lee, and P.-S. Lai, “A case of X-linked adrenal hypoplasia congenita, central precocious puberty and absence of the DAX-1 gene: implications for pubertal regulation,” Hormone Research, vol. 71, no. 5, pp. 298–304, 2009.
[96]  S. Darcan, D. G?ksen, S. ?zen, F. Ozkinay, B. Durmaz, and E. Lalli, “Gonadotropin-dependent precocious puberty in a patient with X-linked adrenal hypoplasia congenita caused by a novel DAX-1 mutation,” Hormone Research in Paediatrics, vol. 75, no. 2, pp. 153–156, 2011.
[97]  S. Domenice, A. C. Latronico, V. N. Brito, I. J. P. Arnhold, F. Kok, and B. B. Mendonca, “Clinical case seminar: adrenocorticotropin-dependent precocious puberty of testicular origin in a boy with X-linked adrenal hypoplasia congenita due to a novel mutation in the DAX1 gene,” Journal of Clinical Endocrinology and Metabolism, vol. 86, no. 9, pp. 4068–4071, 2001.
[98]  M. G. Shaikh, L. Boyes, H. Kingston et al., “Skewed X inactivation is associated with phenotype in a female with adrenal hypoplasia congenita,” Journal of Medical Genetics, vol. 45, no. 9, p. e1, 2008.
[99]  J. K. Phelan and E. R. B. Mccabe, “Mutations in NROB1 (DAX1) and NR5A1 (SF1) responsible for adrenal hypoplasia congenita,” Human Mutation, vol. 18, no. 6, pp. 472–487, 2001.
[100]  L. Lin, W.-X. Gu, G. Ozisik et al., “Analysis of DAX1 (NR0B1) and steroidogenic factor-1 (NR5A1) in children and adults with primary adrenal failure: ten years' experience,” Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 8, pp. 3048–3054, 2006.
[101]  R. El-Khairi, A. Martinez-Aguayo, B. Ferraz-de-Souza, L. Lin, and J. C. Achermann, “Role of DAX-1 (NR0B1) and steroidogenic factor-1 (NR5A1) in human adrenal function,” Endocrine Development, vol. 20, pp. 38–46, 2010.
[102]  P. Bernard, L. Ludbrook, G. Queipo et al., “A familial missense mutation in the hinge region of DAX1 associated with late-onset AHC in a prepubertal female,” Molecular Genetics and Metabolism, vol. 88, no. 3, pp. 272–279, 2006.
[103]  A. Tabarin, J. C. Achermann, D. Recan et al., “A novel mutation in DAX1 causes delayed-onset adrenal insufficiency and incomplete hypogonadotropic hypogonadism,” The Journal of Clinical Investigation, vol. 105, no. 3, pp. 321–328, 2000.
[104]  G. Ozisik, G. Mantovani, J. C. Achermann et al., “An alternate translation initiation site circumvents an amino-terminal DAX1 nonsense mutation leading to a mild form of X-linked adrenal hypoplasia congenita,” Journal of Clinical Endocrinology and Metabolism, vol. 88, no. 1, pp. 417–423, 2003.
[105]  P. Laissue, S. Copelli, I. Bergada et al., “Partial defects in transcriptional activity of two novel DAX-1 mutations in childhood-onset adrenal hypoplasia congenita,” Clinical Endocrinology, vol. 65, no. 5, pp. 681–686, 2006.
[106]  V. Perissi, L. M. Staszewski, E. M. McInerney et al., “Molecular determinants of nuclear receptor-corepressor interaction,” Genes & Development, vol. 13, no. 24, pp. 3198–3208, 1999.
[107]  L. Nagy, H.-Y. Kao, J. D. Love et al., “Mechanism of corepressor binding and release from nuclear hormone receptors,” Genes & Development, vol. 13, no. 24, pp. 3209–3216, 1999.
[108]  H. E. Xu, T. B. Stanley, V. G. Montana et al., “Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPARα,” Nature, vol. 415, no. 6873, pp. 813–817, 2002.
[109]  K. Kawajiri, T. Ikuta, T. Suzuki et al., “Role of the LXXLL-motif and activation function 2 domain in subcellular localization of Dax-1 (dosage-sensitive sex reversal-adrenal hypoplasia congenita critical region on the X chromosome, gene 1),” Molecular Endocrinology, vol. 17, no. 6, pp. 994–1004, 2003.
[110]  M.-C. Battista, M. Otis, M. C?té et al., “Extracellular matrix and hormones modulate DAX-1 localization in the human fetal adrenal gland,” Journal of Clinical Endocrinology and Metabolism, vol. 90, no. 9, pp. 5426–5431, 2005.
[111]  J. O. Scheys, J. H. Heaton, and G. D. Hammer, “Evidence of adrenal failure in aging Dax1-deficient mice,” Endocrinology, vol. 152, no. 9, pp. 3430–3439, 2011.
[112]  C. Dorn, Q. Ou, J. Svaren, P. A. Crawford, and Y. Sadovsky, “Activation of luteinizing hormone β gene by gonadotropin-releasing hormone requires the synergy of early growth response-1 and steroidogenic factor-1,” The Journal of Biological Chemistry, vol. 274, no. 20, pp. 13870–13876, 1999.
[113]  X. Wei, M. Sasaki, H. Huang, V. L. Dawson, and T. M. Dawson, “The orphan nuclear receptor, steroidogenic factor 1, regulates neuronal nitric oxide synthase gene expression in pituitary gonadotropes,” Molecular Endocrinology, vol. 16, no. 12, pp. 2828–2839, 2002.
[114]  S. G. Lehmann, P. Sassone-Corsi, and E. Lalli, “Heat shock affects trafficking of DAX-1 by inducing its rapid and reversible cytoplasmic localization,” Endocrine, vol. 28, no. 2, pp. 137–144, 2005.
[115]  F. Muscatelli, A. P. Walker, E. de Plaen, A. N. Stafford, and A. P. Monaco, “Isolation and characterization of a MAGE gene family in the Xp21.3 region,” Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 11, pp. 4987–4991, 1995.
[116]  B. Dabovic, E. Zanaria, B. Bardoni et al., “A family of rapidly evolving genes from the sex reversal critical region in Xp21,” Mammalian Genome, vol. 6, no. 9, pp. 571–580, 1995.
[117]  A. Swain, V. Narvaez, P. Burgoyne, G. Camerino, and R. Lovell-Badge, “Dax1 antagonizes Sry action in mammalian sex determination,” Nature, vol. 391, no. 6669, pp. 761–767, 1998.
[118]  P. N. Goodfellow and G. Camerino, “DAX-1, an “antitestis” gene,” Cellular and Molecular Life Sciences, vol. 55, no. 6-7, pp. 857–863, 1999.
[119]  R. N. Yu, M. Ito, T. L. Saunders, S. A. Camper, and J. L. Jameson, “Role of Ahch in gonadal development and gametogenesis,” Nature Genetics, vol. 20, no. 4, pp. 353–357, 1998.
[120]  J. J. Meeks, S. E. Crawford, T. A. Russell, K.-I. Morohashi, J. Weiss, and J. L. Jameson, “Dax1 regulates testis cord organization during gonadal differentiation,” Development, vol. 130, no. 5, pp. 1029–1036, 2003.
[121]  B. Jeffs, M. Ito, R. N. Yu et al., “Sertoli cell-specific rescue of fertility, but not testicular pathology, in Dax1 (Ahch)-deficient male mice,” Endocrinology, vol. 142, no. 6, pp. 2481–2488, 2001.
[122]  J. J. Meeks, T. A. Russell, B. Jeffs, I. Huhtaniemi, J. Weiss, and J. L. Jameson, “Leydig cell-specific expression of DAX1 improves fertility of the Dax1-deficient mouse,” Biology of Reproduction, vol. 69, no. 1, pp. 154–160, 2003.
[123]  B. Jeffs, J. J. Meeks, M. Ito et al., “Blockage of the rete testis and efferent ductules by ectopic sertoli and leydig cells causes infertility in Dax1-deficient male mice,” Endocrinology, vol. 142, no. 10, pp. 4486–4495, 2001.
[124]  Z. J. Wang, B. Jeffs, M. Ito et al., “Aromatase (Cyp19) expression is up-regulated by targeted disruption of Dax1,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 14, pp. 7988–7993, 2001.
[125]  J. J. Meeks, J. Weiss, and J. L. Jameson, “Dax1 is required for testis determination,” Nature Genetics, vol. 34, no. 1, pp. 32–33, 2003.
[126]  G. J. Bouma, K. H. Albrecht, L. L. Washburn, A. K. Recknagel, G. A. Churchill, and E. M. Eicher, “Gonadal sex reversal in mutant Dax1 XY mice: a failure to upregulate Sox9 in pre-Sertoli cells,” Development, vol. 132, no. 13, pp. 3045–3054, 2005.
[127]  S. Y. Park, J. J. Meeks, G. Raverot et al., “Nuclear receptors Sf1 and Dax1 function cooperatively to mediate somatic cell differentiation during testis development,” Development, vol. 132, no. 10, pp. 2415–2423, 2005.
[128]  S. B. Seminara, J. C. Achermann, M. Genel, J. L. Jameson, and W. F. Crowley Jr., “X-linked adrenal hypoplasia congenita: a mutation in DAX1 expands the phenotypic spectrum in males and females,” Journal of Clinical Endocrinology and Metabolism, vol. 84, no. 12, pp. 4501–4509, 1999.
[129]  L. M. Ludbrook, P. Bernard, S. Bagheri-Fam et al., “Excess DAX1 leads to XY ovotesticular disorder of sex development (DSD) in mice by inhibiting steroidogenic factor-1 (SF1) activation of the testis enhancer of SRY-box-9 (Sox9),” Endocrinology, vol. 153, no. 4, pp. 1948–1958, 2012.
[130]  I. Chambers and A. Smith, “Self-renewal of teratocarcinoma and embryonic stem cells,” Oncogene, vol. 23, no. 43, pp. 7150–7160, 2004.
[131]  S. Yamanaka, “Strategies and new developments in the generation of patient-specific pluripotent stem cells,” Cell Stem Cell, vol. 1, no. 1, pp. 39–49, 2007.
[132]  K. Mitsui, Y. Tokuzawa, H. Itoh et al., “The homeoprotein nanog is required for maintenance of pluripotency in mouse epiblast and ES cells,” Cell, vol. 113, no. 5, pp. 631–642, 2003.
[133]  K. K. Niakan, E. C. Davis, R. C. Clipsham et al., “Novel role for the orphan nuclear receptor Dax1 in embryogenesis, different from steroidogenesis,” Molecular Genetics and Metabolism, vol. 88, no. 3, pp. 261–271, 2006.
[134]  Y.-H. Loh, Q. Wu, J.-L. Chew et al., “The Oct4 and Nanog transcription network regulates pluripotency in mouse embryonic stem cells,” Nature Genetics, vol. 38, no. 4, pp. 431–440, 2006.
[135]  J. Wang, S. Rao, J. Chu et al., “A protein interaction network for pluripotency of embryonic stem cells,” Nature, vol. 444, no. 7117, pp. 364–368, 2006.
[136]  J. Kim, J. Chu, X. Shen, J. Wang, and S. H. Orkin, “An extended transcriptional network for pluripotency of embryonic stem cells,” Cell, vol. 132, no. 6, pp. 1049–1061, 2008.
[137]  C. Sun, Y. Nakatake, H. Ura et al., “Stem cell-specific expression of Dax1 is conferred by STAT3 and Oct3/4 in embryonic stem cells,” Biochemical and Biophysical Research Communications, vol. 372, no. 1, pp. 91–96, 2008.
[138]  D. L. C. van den Berg, T. Snoek, N. P. Mullin et al., “An Oct4-centered protein interaction network in embryonic stem cells,” Cell Stem Cell, vol. 6, no. 4, pp. 369–381, 2010.
[139]  H. Niwa, J.-I. Miyazaki, and A. G. Smith, “Quantitative expression of Oct-3/4 defines differentiation, dedifferentiation or self-renewal of ES cells,” Nature Genetics, vol. 24, no. 4, pp. 372–376, 2000.
[140]  O. Khalfallah, M. Rouleau, P. Barbry, B. Bardoni, and E. Lalli, “Dax-1 knockdown in mouse embryonic stem cells induces loss of pluripotency and multilineage differentiation,” Stem Cells, vol. 27, no. 7, pp. 1529–1537, 2009.
[141]  E. Lalli and J. Alonso, “Targeting DAX-1 in embryonic stem cells and cancer,” Expert Opinion on Therapeutic Targets, vol. 14, no. 2, pp. 169–177, 2010.
[142]  J.-C. D. Heng, B. Feng, J. Han et al., “The nuclear receptor Nr5a2 can replace Oct4 in the reprogramming of murine somatic cells to pluripotent cells,” Cell Stem Cell, vol. 6, no. 2, pp. 167–174, 2010.
[143]  C.-Q. Xie, Y. Jeong, M. Fu et al., “Expression profiling of nuclear receptors in human and mouse embryonic stem cells,” Molecular Endocrinology, vol. 23, no. 5, pp. 724–733, 2009.
[144]  M. Reincke, F. Beuschlein, E. Lalli et al., “DAX-1 expression in human adrenocortical neoplasms: implications for steroidogenesis,” Journal of Clinical Endocrinology and Metabolism, vol. 83, no. 7, pp. 2597–2600, 1998.
[145]  H. Shibata, Y. Ikeda, T. Mukai et al., “Expression profiles of COUP-TF, DAX-1, and SF-1 in the human adrenal gland and adrenocortical tumors: possible implications in steroidogenesis,” Molecular Genetics and Metabolism, vol. 74, no. 1-2, pp. 206–216, 2001.
[146]  L. A. Helguero, M. Hedengran Faulds, C. F?rster, J.-?. Gustafsson, and L.-A. Haldosén, “DAX-1 expression is regulated during mammary epithelial cell differentiation,” Endocrinology, vol. 147, no. 7, pp. 3249–3259, 2006.
[147]  E. Lalli, “Methodological pitfalls in the study of DAX-1 function,” Cell Death and Disease, vol. 5, article e977, 2014.
[148]  S. Ikuyama, Y.-M. Mu, K. Ohe et al., “Expression of an orphan nuclear receptor DAX-1 in human pituitary adenomas,” Clinical Endocrinology, vol. 48, no. 5, pp. 647–654, 1998.
[149]  S. J. B. Aylwin, J. P. Welch, C. L. Davey et al., “The relationship between steroidogenic factor 1 and DAX-1 expression and in vitro gonadotropin secretion in human pituitary adenomas,” Journal of Clinical Endocrinology and Metabolism, vol. 86, no. 6, pp. 2476–2483, 2001.
[150]  M. Abd-Elaziz, J.-I. Akahira, T. Moriya, T. Suzuki, N. Yaegashi, and H. Sasano, “Nuclear receptor DAX-1 in human common epithelial ovarian carcinoma: an independent prognostic factor of clinical outcome,” Cancer Science, vol. 94, no. 11, pp. 980–985, 2003.
[151]  I. Conde, J. M. Alfaro, B. Fraile, A. Ruíz, R. Paniagua, and M. I. Arenas, “DAX-1 expression in human breast cancer: comparison with estrogen receptors ER-alpha, ER-beta and androgen receptor status,” Breast Cancer Research, vol. 6, no. 3, pp. R140–R148, 2004.
[152]  S. Saito, K. Ito, T. Suzuki et al., “Orphan nuclear receptor DAX-1 in human endometrium and its disorders,” Cancer Science, vol. 96, no. 10, pp. 645–652, 2005.
[153]  Y. Nakamura, T. Suzuki, Y. Arai, and H. Sasano, “Nuclear receptor DAX1 in human prostate cancer: a novel independent biological modulator,” Endocrine Journal, vol. 56, no. 1, pp. 39–44, 2009.
[154]  D.-C. Seo, J.-M. Sung, H.-J. Cho et al., “Gene expression profiling of cancer stem cell in human lung adenocarcinoma A549 cells,” Molecular Cancer, vol. 6, article 75, 2007.
[155]  T. Oda, T. Tian, M. Inoue et al., “Tumorigenic role of orphan nuclear receptor NR0B1 in lung adenocarcinoma,” American Journal of Pathology, vol. 175, no. 3, pp. 1235–1245, 2009.
[156]  A. Arvand and C. T. Denny, “Biology of EWS/ETS fusions in Ewing's family tumors,” Oncogene, vol. 20, no. 40, pp. 5747–5754, 2001.
[157]  M. Mendiola, J. Carrillo, E. García et al., “The orphan nuclear receptor DAX1 is up-regulated by the EWS/FLI1 oncoprotein and is highly expressed in Ewing tumors,” International Journal of Cancer, vol. 118, no. 6, pp. 1381–1389, 2006.
[158]  M. Kinsey, R. Smith, and S. L. Lessnick, “NR0B1 is required for the oncogenic phenotype mediated by EWS/FLI in Ewing's sarcoma,” Molecular Cancer Research, vol. 4, no. 11, pp. 851–859, 2006.
[159]  M. Wachtel, M. Dettling, E. Koscielniak et al., “Gene expression signatures identify rhabdomyosarcoma subtypes and detect a novel t(2;2)(q35;p23) translocation fusing PAX3 to NCOA1,” Cancer Research, vol. 64, no. 16, pp. 5539–5545, 2004.
[160]  E. García-Aragoncillo, J. Carrillo, E. Lalli et al., “DAX1, a direct target of EWS/FLI1 oncoprotein, is a principal regulator of cell-cycle progression in Ewing's tumor cells,” Oncogene, vol. 27, no. 46, pp. 6034–6043, 2008.
[161]  K. Gangwal, S. Sankar, P. C. Hollenhorst et al., “Microsatellites as EWS/FLI response elements in Ewing's sarcoma,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 29, pp. 10149–10154, 2008.

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133